{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:14:24Z","timestamp":1754162064425,"version":"3.41.2"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>While the superiority of reabsorbable-polymer drug-eluting stents (RP-DES) over bare-metal stents and first-generation durable-polymer (DP)-DES has been largely established, their advantage compared with new-generation DP-DES is still controversial. This study aimed was to compare clinical outcomes of all-comer patients undergoing percutaneous coronary intervention (PCI) with new generation DP-DES or RP-DES implantation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We prospectively enrolled 679 consecutive patients treated with PCI with RP-DES or DP-DES. The primary endpoint was the 1-year incidence of major adverse clinical events (MACE), a composite of death, myocardial infarction (MI), and target vessel revascularization (TVR). Target lesion revascularization (TLR) and definite stent thrombosis were also recorded.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 439 (64.6%) received RP-DES and 240 (36.4%) received DP-DES. No significant difference in the incidence of MACE (5.9 vs. 4.9%; hazard ratio, 1.23; 95% confidence interval (CI), 0.61\u20132.49; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.569), death (1.8 vs. 1.7%; hazard ratio, 1.09; 95% CI, 0.33\u20133.64; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.882), MI (2.3 vs. 2.1%; hazard ratio, 1.05; 95% CI, 0.36\u20133.08; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.927), TVR (2.3 vs. 1.3%; hazard ratio, 1.70; 95% CI, 0.47\u20136.20; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.418), TLR (1.4 vs. 0.4%; hazard ratio, 3.06; 95% CI, 0.37\u201325.40; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.301), and definite stent thrombosis (0.5 vs. 0.4%; hazard ratio, 1.09; 95% CI, 0.10\u201312.10; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.942) was observed between RP-DES and DP-DES patients at 1-year follow-up. These results were confirmed in a propensity score-matched cohort (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2009=\u2009134 per group).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In our registry including a real-world population of all-comer patients undergoing PCI, RP-DES, or durable polymer-DES showed similar efficacy and safety at a 1-year follow-up.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000000993","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T01:15:39Z","timestamp":1606180539000},"page":"281-287","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["REabsorbable vs. DUrable Polymer Drug-Eluting Stents in All-Comer PatiEnts: the REDUCE registry"],"prefix":"10.1097","volume":"32","author":[{"given":"Francesco","family":"Piccirillo","sequence":"first","affiliation":[{"name":"Unit of Cardiovascular Science, Department of Medicine, Campus Bio-Medico University, Rome"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Caiazzo","sequence":"additional","affiliation":[{"name":"Unit of Cardiovascular Science, Department of Medicine, Campus Bio-Medico University, Rome"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Miglionico","sequence":"additional","affiliation":[{"name":"Unit of Cardiovascular Science, Department of Medicine, Campus Bio-Medico University, Rome"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annunziata","family":"Nusca","sequence":"additional","affiliation":[{"name":"Unit of Cardiovascular Science, Department of Medicine, Campus Bio-Medico University, Rome"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosetta","family":"Melfi","sequence":"additional","affiliation":[{"name":"Unit of Cardiovascular Science, Department of Medicine, Campus Bio-Medico University, Rome"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Gallo","sequence":"additional","affiliation":[{"name":"Unit of Cardiovascular Science, Department of Medicine, Campus Bio-Medico University, Rome"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Ricottini","sequence":"additional","affiliation":[{"name":"Unit of Cardiovascular Science, Department of Medicine, Campus Bio-Medico University, Rome"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"De Michele","sequence":"additional","affiliation":[{"name":"Cardiology Unit, \u201cSan Giuseppe Moscati\u201d Hospital, Aversa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Golino","sequence":"additional","affiliation":[{"name":"Cardiology Unit, \u201cSan Giuseppe Moscati\u201d Hospital, Aversa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Manganiello","sequence":"additional","affiliation":[{"name":"Cardiology Unit, \u201cSan Giuseppe Moscati\u201d Hospital, Aversa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Fattore","sequence":"additional","affiliation":[{"name":"Cardiology Unit, \u201cSan Giuseppe Moscati\u201d Hospital, Aversa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Mangiacapra","sequence":"additional","affiliation":[{"name":"Unit of Cardiovascular Science, Department of Medicine, Campus Bio-Medico University, Rome"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Germano","family":"Di Sciascio","sequence":"additional","affiliation":[{"name":"Unit of Cardiovascular Science, Department of Medicine, Campus Bio-Medico University, Rome"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/0002-8703(93)91013-5","article-title":"Definition and measurement of restenosis after successful coronary angioplasty: implications for clinical trials.","volume":"125","author":"Lesp\u00e9rance","year":"1993","journal-title":"Am Heart J"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jacc.2010.07.016","article-title":"Stent thrombosis.","volume":"56","author":"Holmes","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/01.CIR.0000025585.63486.59","article-title":"Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial.","volume":"106","author":"Serruys","year":"2002","journal-title":"Circulation"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","article-title":"Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.","volume":"48","author":"Joner","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"e000064","DOI":"10.1136\/openhrt-2014-000064","article-title":"First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31\u2009379 patients.","volume":"1","author":"Navarese","year":"2014","journal-title":"Open Heart"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"3872704","DOI":"10.1155\/2020\/3872704","article-title":"Safety and efficacy of second-generation drug-eluting stents in real-world practice: insights from the Multicenter Grand-DES Registry.","volume":"2020","author":"Ki","year":"2020","journal-title":"J Interv Cardiol"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1021\/acs.bioconjchem.5b00192","article-title":"Polymer-free drug-eluting stents: an overview of coating strategies and comparison with polymer-coated drug-eluting stents.","volume":"26","author":"Chen","year":"2015","journal-title":"Bioconjug Chem"},{"issue":"Suppl F","key":"R8-20250729","doi-asserted-by":"crossref","first-page":"F28","DOI":"10.4244\/EIJV5IFA5","article-title":"The bioabsorption process: tissue and cellular mechanisms and outcomes.","volume":"5","author":"Vorpahl","year":"2009","journal-title":"Eurointervention"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jacc.2013.09.061","article-title":"Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.","volume":"63","author":"Palmerini","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"e003255","DOI":"10.1161\/JAHA.116.003255","article-title":"Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stent for percutaneous coronary revascularization: 2-year results of the BIOSCIENCE trial.","volume":"5","author":"Zbinden","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","article-title":"Fourth universal definition of myocardial infarction (2018).","volume":"72","author":"Thygesen","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions.","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects.","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1210816","article-title":"Drug-eluting coronary-artery stents.","volume":"368","author":"Stefanini","year":"2013","journal-title":"N Engl J Med"},{"key":"R15-20250729","first-page":"330","article-title":"Stent thrombosis with second- versus first-generation drug-eluting stents in real-world percutaneous coronary intervention: analysis of 3806 consecutive procedures from a large-volume single-center prospective registry.","volume":"25","author":"Dores","year":"2013","journal-title":"J Invasive Cardiol"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/heartjnl-2014-305743","article-title":"Stent thrombosis in early-generation drug-eluting stents versus newer-generation everolimus-eluting stent assorted by LVEF.","volume":"101","author":"van Boven","year":"2015","journal-title":"Heart"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jcin.2012.02.014","article-title":"Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study.","volume":"5","author":"Naidu","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1586\/erc.12.29","article-title":"No country for old stents? Improving long-term patient outcomes with biodegradable polymer drug-eluting stents.","volume":"10","author":"Byrne","year":"2012","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"f6530","DOI":"10.1136\/bmj.f6530","article-title":"Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis.","volume":"347","author":"Navarese","year":"2013","journal-title":"BMJ"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF00239417","article-title":"Biocompatibility of biodegradable and nonbiodegradable polymer-coated stents implanted in porcine peripheral arteries.","volume":"18","author":"De Scheerder","year":"1995","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1161\/01.CIR.94.7.1690","article-title":"Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries.","volume":"94","author":"van der Giessen","year":"1996","journal-title":"Circulation"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jcin.2015.03.029","article-title":"Acute thrombogenicity of a durable polymer everolimus-eluting stent relative to contemporary drug-eluting stents with biodegradable polymer coatings assessed ex vivo in a swine shunt model.","volume":"8","author":"Otsuka","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.jcin.2017.06.059","article-title":"Endothelial barrier protein expression in biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting metallic stents.","volume":"10","author":"Mori","year":"2017","journal-title":"JACC Cardiovascu Interv"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jcin.2016.12.002","article-title":"Meta-analysis of randomized clinical trials comparing biodegradable polymer drug-eluting stent to second-generation durable polymer drug-eluting stents.","volume":"10","author":"El-Hayek","year":"2017","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:07:54Z","timestamp":1753812474000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000993","relation":{},"ISSN":["0954-6928"],"issn-type":[{"type":"print","value":"0954-6928"}],"subject":[],"published":{"date-parts":[[2020,11,20]]}}}